LON:AVCT Avacta Group (AVCT) Share Price, News & Analysis GBX 54 +4.00 (+8.00%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlines About Avacta Group Stock (LON:AVCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avacta Group alerts:Sign Up Key Stats Today's Range 48▼ 5550-Day Range 44.20▼ 7752-Week Range 39.63▼ 152Volume1.99 million shsAverage Volume2.39 million shsMarket Capitalization£193.48 millionP/E RatioN/ADividend Yield3.97%Price TargetN/AConsensus RatingN/A Company OverviewAvacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Receive AVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter. Email Address AVCT Stock News HeadlinesAvacta Group Share Chat (AVCT)October 3, 2024 | lse.co.ukAvacta Group First Half 2024 Earnings: UK£0.038 loss per share (vs UK£0.043 loss in 1H 2023)October 3, 2024 | uk.finance.yahoo.comSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.November 2, 2024 | Chaikin Analytics (Ad)Avacta Group Plc (AVCTF)July 27, 2024 | uk.finance.yahoo.comAvacta Group Plc reports FY resultsMay 1, 2024 | msn.comAvacta Group (LON:AVCT) investors are sitting on a loss of 82% if they invested three years agoMay 1, 2024 | finance.yahoo.comUpdated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024March 6, 2024 | finance.yahoo.comAvacta Group: Appointment of Chief Business OfficerDecember 19, 2023 | finanznachrichten.deSee More Headlines AVCT Stock Analysis - Frequently Asked Questions How have AVCT shares performed this year? Avacta Group's stock was trading at GBX 116.50 at the beginning of the year. Since then, AVCT shares have decreased by 53.6% and is now trading at GBX 54. View the best growth stocks for 2024 here. How were Avacta Group's earnings last quarter? Avacta Group Plc (LON:AVCT) released its quarterly earnings data on Monday, September, 28th. The biotechnology company reported ($3.74) earnings per share (EPS) for the quarter. Avacta Group had a negative trailing twelve-month return on equity of 73.02% and a negative net margin of 114.45%. How do I buy shares of Avacta Group? Shares of AVCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Avacta Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avacta Group investors own include Legal & General Group (LGEN), Lloyds Banking Group (LLOY), Lloyds Banking Group (LYG), IQE (IQE), Barclays (BARC), Meta Platforms (META) and Revvity (PKI). Company Calendar Last Earnings9/28/2020Today11/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:AVCT CUSIPN/A CIKN/A Webwww.avacta.com Phone+44-1904-217070FaxN/AEmployees120Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-25,890,000.00 Net Margins-114.45% Pretax MarginN/A Return on Equity-73.02% Return on Assets-21.80% Debt Debt-to-Equity Ratio63.54 Current Ratio1.29 Quick Ratio4.96 Sales & Book Value Annual Sales£22.62 million Price / Sales8.55 Cash FlowGBX 3.60 per share Price / Cash Flow15.00 Book ValueGBX 14 per share Price / Book3.86Miscellaneous Outstanding Shares358,300,000Free FloatN/AMarket Cap£193.48 million OptionableNot Optionable Beta1.12 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (LON:AVCT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avacta Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avacta Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.